A pilot dose finding study of MUC1 vaccine in conjunction with poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose) or Hiltonol in patients with recurrent and/or advanced prostate cancer.

Trial Profile

A pilot dose finding study of MUC1 vaccine in conjunction with poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose) or Hiltonol in patients with recurrent and/or advanced prostate cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Prostate cancer vaccine (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 08 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 30 Apr 2015 Planned End Date changed from 1 Jul 2014 to 1 Dec 2015 as per ClinicalTrials.gov record.
    • 25 Sep 2013 Planned end date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top